Page last updated: 2024-12-10

7432 s

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ceftibuten: A cephalosporin antibacterial agent that is used in the treatment of infections, including urinary-tract and respiratory-tract infections. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ceftibuten : A third-generation cephalosporin antibiotic with a [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino substituent at the 7 position of the cephem skeleton. An orally-administered agent, ceftibuten is used as the dihydrate to treat urinary-tract and respiratory-tract infections. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5282242
CHEMBL ID1605
CHEBI ID3510
SCHEMBL ID37054
MeSH IDM0153546

Synonyms (86)

Synonym
chebi:3510 ,
7beta-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-3,4-didehydrocepham-4-carboxylic acid
ceftibutenum
ceftibutene
(6r,7r)-7-{[(2z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
keimax
sch-39720
7432-s
ceprifran
ceftem
SPECTRUM5_001558
BSPBIO_002733
NCGC00178501-01
ceftibuten
C08117
ceftibuteno
(+)-(6r,7r)-7-((z)-2-(2-amino-4-thiazolyl)-4-carboxycrotonamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
DB01415
cis-ceftibuten
D00922
ceftibuten (usan/inn)
ceftibutene [inn-french]
cephalosporin 7432-s
s 7432
ceftibutenum [inn-latin]
ceftibuteno [inn-spanish]
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-butenyl)amino)-8-oxo-, (6r-(6alpha,7beta(z)))-
ceftibuten [usan:inn:ban]
antibiotic 7432s
sch 39720
cis-ceftibutin
SPECTRUM1505207
HMS2093K18
AKOS005146205
nsc-758925
ceftibutin
CHEMBL1605
achn383
achn-383
HMS1922L17
7-(2-(2-amino-4-thiazolyl)-4-carboxy-2-butenoylamino)-3-cephem-4-carboxylic acid
C-2550
nsc 758925
iw71n46b4y ,
unii-iw71n46b4y
pharmakon1600-01505207
nsc758925
tox21_111446
dtxsid4045925 ,
cas-97519-39-6
dtxcid2025925
CCG-39440
bdbm50370586
ceftibuten [mi]
ceftibuten [usan]
ceftibutin [vandf]
ceftibuten [inn]
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-butenyl)amino)-8-oxo-, (6r-(6.alpha.,7.beta.(z)))-
ceftibuten [vandf]
ceftibuten [who-dd]
AKOS015854930
ceftibuten-13c3
HY-B0698
SCHEMBL37054
ceftibuten, antibiotic for culture media use only
AB01563048_01
(6r,7r)-7-[(2z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
sr-05000001989
SR-05000001989-1
SBI-0206740.P001
HMS3715P10
C3391
(6r,7r)-7-[[(2z)-2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-buten-1-yl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Q419521
NCGC00178501-04
97519-39-6 (free)
7-[2-(2-amino-1,3-thiazol-4-yl)-4-carboxyisocrotonamide]-3-cephem-4-carboxylicacid
(6r,7r)-7-[[(z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
gtpl12029
EN300-21702502
j01da39
ceftibutene (inn-french)
(6r,7r)-7-(((2z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl)amino)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
ceftibutenum (inn-latin)
7beta-(((2z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl)amino)-3,4-didehydrocepham-4-carboxylic acid
ceftibuteno (inn-spanish)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The incidence of adverse events was higher in the co-amoxiclav-treated patients (31% versus 15% in the ceftibuten group) as was the incidence of severe events (10% for co-amoxiclav-treated patients versus < 1% in the ceftibuten group)."( The efficacy and safety of once-daily ceftibuten compared with co-amoxiclav in the treatment of acute bacterial sinusitis.
De Abate, CA; Dennington, ML; Perrotta, RJ; Ziering, RM, 1992
)
0.28
" 7432-S was concluded to be safe and well tolerated."( Phase I clinical studies of 7432-S, a new oral cephalosporin: safety and pharmacokinetics.
Iida, M; Ishii, H; Kitagawa, K; Mizuno, A; Nakashima, M; Oguma, T; Takiguchi, Y; Uematsu, T; Yamamoto, S; Yoshida, T, 1988
)
0.27
" Adverse experiences were collected by voluntary reports by physicians from direct observations, parental and/or patient complaints in 1152 patients."( Worldwide safety experience with ceftibuten pediatric suspension.
Reidenberg, BE, 1995
)
0.29
" Adverse experiences were, in general, few and mild, being reported in 8% and 17% of patients receiving ceftibuten and cefaclor, respectively."( Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of pneumonia and bronchiectasis.
McCabe, R; Mogabgab, W; Perrotta, R; Rumans, L, 1993
)
0.29
"5%) and also the incidence of adverse events which occurred in 24/163 (14."( Comparison of the efficacy and safety of a short course of ceftibuten with that of amoxycillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis.
Guest, N; Langan, CE, 1998
)
0.3
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32

Pharmacokinetics

ExcerptReferenceRelevance
" To assess the pharmacokinetic characteristics of CFB in pediatric patients, we completed a multicenter investigation of 49 children (26 females) between the ages of 6 months and 17 years who had normal hepatic and renal functions and no evidence of chronic disease."( Single-dose pharmacokinetics of ceftibuten (SCH 39720) in infants and children.
Ardite, M; Blumer, JL; Jacobs, RF; Kearns, GL; Reed, MD; Yogev, RD, 1991
)
0.28
" The half-life is relatively long for this class of drugs, being approximately 2-3 hr."( The pharmacokinetics of ceftibuten in humans.
Affrime, M; Barr, WH; Lim, J; Lin, CC; Radwanski, E; Symchowicz, S,
)
0.13
" Ceftibuten failed to alter either the systemic clearance of theophylline (CL), its volume of distribution (Vss), or its elimination half-life (t1/2)."( Failure of ceftibuten to alter single dose theophylline clearance.
Bachmann, K; Jauregui, L; Martin, M; Nunlee, M; Schwartz, J, 1990
)
0.28
"5 mg/kg produced Cmax and area under the plasma concentration-time curve values that were dose-proportional."( Pharmacokinetics of ceftibuten in children.
Affrime, M; Barr, WH; Batra, V; Lin, CC, 1995
)
0.29
" The half-life (2."( Multiple-dose pharmacokinetics of ceftibuten in healthy volunteers.
Affrime, M; Cayen, MN; Lin, C; Radwanski, E, 1995
)
0.29
" The methods were applied to pharmacokinetic studies of ceftibuten after multiple oral administration (400 mg every 12 h for 8 days) to healthy volunteers."( High-performance liquid chromatographic determination of ceftibuten and its metabolite in biological fluids: applications in pharmacokinetic studies.
Bressolle, F; Fabre, D; Galtier, M; Goncalves, F; Kinowski, JM; Rouzier-Panis, R, 1994
)
0.29
" These pharmacokinetic data can be used as a basis to compare the four oral cephalosporins; however, comparative susceptibility data must also be considered."( Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers.
Affrime, MB; Hyatt, JM; Nix, DE; Reidenberg, P; Symonds, WT; Teal, MA; Wilton, JH,
)
0.13
" Pharmacokinetic analyses of CETB after intraintestinal administration demonstrated that both Cmax and area under the plasma concentration-time curve from 0 to 3 h were greater at 8:00 PM than at 8:00 AM in fed rats."( Altered diurnal rhythm of intestinal peptide transporter by fasting and its effects on the pharmacokinetics of ceftibuten.
Inui, K; Okuda, M; Pan, X; Terada, T, 2003
)
0.32

Compound-Compound Interactions

ExcerptReferenceRelevance
"The bactericidal effects of ceftibuten in combination with netilmicin, isepamicin or ciprofloxacin against two strains of Escherichia coli and three of Klebsiella pneumoniae were studied by the killing curve method."( A statistical evaluation of the bactericidal effects of ceftibuten in combination with aminoglycosides and ciprofloxacin.
Carret, G; Flandrois, JP; Guérillot, F, 1993
)
0.29
"An agar dilution checkerboard method was used to evaluate the in vitro activity of omeprazole combined with clarithromycin, amoxicillin, and ceftibuten, respectively, against clinical isolates of Helicobacter pylori."( In vitro activity of omeprazole in combination with several antimicrobial agents against clinical isolates of Helicobacter pylori.
Alarcón, T; Díaz de Rojas, F; Domingo, D; López-Brea, M; Sánchez, I, 1996
)
0.29
" These parameters were somewhat higher when ceftibuten was administered with ranitidine, but they were still within the ranges seen in normal healthy volunteers."( Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid mylanta double- strength liquid or with ranitidine.
Affrime, M; Cutler, D; Lin, CC; Nomeir, A; Radwanski, E, 1998
)
0.3
" Although the participation of the particular transporters in observed drug-drug interactions can be difficult to confirm in humans, this review focuses mainly on pharmacokinetic interactions of clinically important drugs."( Transporter-mediated Drug Interactions.
Tsuji, A, 2002
)
0.31

Bioavailability

ExcerptReferenceRelevance
" Ceftibuten is very well absorbed in young and old patients."( The pharmacokinetics of ceftibuten in humans.
Affrime, M; Barr, WH; Lim, J; Lin, CC; Radwanski, E; Symchowicz, S,
)
0.13
" Pharmacokinetic studies have shown that the molecule has an oral bioavailability higher than 90% of the administered dose (reaching peak serum concentrations of 5-19 mg/l after a single dose of 200 and 400 mg)."( Concentrations of ceftibuten in bronchial secretions.
Arcidiacono, M; Cocuzza, C; Demartini, G; Fraschini, F; Scaglione, F; Triscari, F,
)
0.13
"The bioavailability and pharmacokinetics of ceftibuten administered as an oral suspension were characterized by several studies in young healthy male adults (19 to 39 years old) and children ranging in age from 6 months to 17 years."( Pharmacokinetics of ceftibuten in children.
Affrime, M; Barr, WH; Batra, V; Lin, CC, 1995
)
0.29
" Although the absolute bioavailability of ceftibuten in humans is not known, its relative bioavailability indicates that there is relatively rapid and complete absorption of the drug."( Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use.
Kearns, GL; Young, RA, 1994
)
0.29
"The comparative bioavailability of ceftibuten, a new third-generation cephalosporin antibiotic given orally once daily, in capsule and suspension dosage forms, was assessed in healthy male subjects."( Comparative bioavailability of ceftibuten in capsule and suspension forms.
Affrime, M; Cayen, MN; Colucci, R; Lim, J; Lin, CC; Radwanski, E,
)
0.13
" Bioavailability parameters, maximum plasma concentration and area under the plasma concentration-time curve to infinity of ceftibuten were unaffected by treatment with antacid."( Pharmacokinetic drug interaction study: administration of ceftibuten concurrently with the antacid mylanta double- strength liquid or with ranitidine.
Affrime, M; Cutler, D; Lin, CC; Nomeir, A; Radwanski, E, 1998
)
0.3
"The utilization of the membrane transport protein PEPT1 as a drug delivery system is a promising strategy to enhance the oral bioavailability of drugs."( Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I, 2005
)
0.33
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Ledaborbactam (formerly VNRX-5236) is a novel orally bioavailable β-lactamase inhibitor that restores ceftibuten activity against Ambler Class A-, C- and D-producing Enterobacterales."( In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combination.
Asempa, TE; Avery, LM; Fratoni, AJ; Nicolau, DP, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" Its antimicrobial spectrum and dosage formulation suggest a use for CFB in the treatment of otitis media and upper and lower respiratory and urinary tract infections in infants and children."( Single-dose pharmacokinetics of ceftibuten (SCH 39720) in infants and children.
Ardite, M; Blumer, JL; Jacobs, RF; Kearns, GL; Reed, MD; Yogev, RD, 1991
)
0.28
" Thus, ceftibuten, with a once- or twice-daily oral dosage regimen, good tolerability profile and activity against a wide range of bacterial organisms, offers a promising alternative to other agents (including cefaclor, cotrimoxazole, amoxicillin/clavulanic acid, bacampicillin and phenoxymethylpenicillin) for the treatment of patients with urogenital and respiratory tract infections."( Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
Balfour, JA; Wiseman, LR, 1994
)
0.29
" Compliance with dosing was assessable with weight of drug consumed in 127 patients in each treatment group."( Multicenter controlled trial comparing ceftibuten with amoxicillin/clavulanate in the empiric treatment of acute otitis media. Members of the Ceftibuten Otitis Media United States Study Group.
Mccarty, JM; Mclinn, SE; Perrotta, R; Pichichero, ME; Reidenberg, BE, 1995
)
0.29
"Ceftibuten suspension was administered to 1312 pediatric patients in clinical trials at a dosage of 9 mg/kg once daily, with a maximal daily dose of 400 mg."( Worldwide safety experience with ceftibuten pediatric suspension.
Reidenberg, BE, 1995
)
0.29
" Blood levels achieved after a single 400-mg dose given once daily or 9 mg/kg/day taken once daily for children yield blood levels and postantibiotic inhibition for the majority of a dosing period."( Ceftibuten: minimal inhibitory concentrations, postantibiotic effect and beta-lactamase stability--a rationale for dosing programs.
Neu, HC, 1995
)
0.29
" The area under the plasma concentration versus time curve from 0 to infinity and the Cmax of this drug were significantly higher on day 8 than the values predicted from the elimination half-life computed on day 1 of treatment and the dosing interval."( Multiple-dose pharmacokinetics of ceftibuten after oral administration to healthy volunteers.
Bressolle, F; Edno, L; Galtier, M; Gomeni, R; Goncalves, F; Kinowski, JM; Panis, R, 1994
)
0.29
" The abilities of the drugs to protect mice against the organisms were determined in mouse protection tests, and the doses were fractionated to produce various dosing regimens with different times above the MIC."( Optimal times above MICs of ceftibuten and cefaclor in experimental intra-abdominal infections.
Nicolau, DP; Nightingale, CH; Onyeji, CO; Quintiliani, R, 1994
)
0.29
"In a multicentre, international study of 187 adult patients with bacterial pneumonia or bronchiectasis, the safety and efficacy of a regimen of 200 mg ceftibuten administered twice-daily was compared with cefaclor given in a dosage of 500 mg three times a day."( Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of pneumonia and bronchiectasis.
McCabe, R; Mogabgab, W; Perrotta, R; Rumans, L, 1993
)
0.29
" Plasma and MEF collected at 2, 4, 6, or 12 h after at least 3 days of dosing were analyzed for ceftibuten by a high-pressure liquid chromatography method, and the data were used to calculate pharmacokinetic parameters."( Penetration of ceftibuten into middle ear fluid.
Kumari, P; Lin, C; Perrotta, RJ; Reidenberg, BE, 1996
)
0.29
" The once-daily dosing schedule for ceftibuten therapy may aid patient compliance, particularly in the pediatric population."( Comparison of the efficacy and tolerability of once-daily ceftibuten and twice-daily cefprozil in the treatment of children with acute otitis media.
Blumer, JL; Forti, WP; Summerhouse, TL,
)
0.13
"The comparative bioavailability of ceftibuten, a new third-generation cephalosporin antibiotic given orally once daily, in capsule and suspension dosage forms, was assessed in healthy male subjects."( Comparative bioavailability of ceftibuten in capsule and suspension forms.
Affrime, M; Cayen, MN; Colucci, R; Lim, J; Lin, CC; Radwanski, E,
)
0.13
" Elimination occurs primarily through the kidneys, requiring dosage adjustments to be made when creatinine clearance falls below 50 ml/minute."( Ceftibuten: an overview.
Nicolau, DP; Nightingale, CH; Owens, RC,
)
0.13
"Ceftibuten is an alternative to other antimicrobial agents with convenient once-daily dosing in the treatment of upper and lower respiratory tract infections."( Ceftibuten: a new expanded-spectrum oral cephalosporin.
Guay, DR, 1997
)
0.3
" Middle ear fluid was extracted by tympanocentesis 4, 12 and 24 h after dosing and divided into two fractions: with cells (as collected) (C+) and cell-free (C-)."( Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibuten, cefixime and azithromycin.
Arcidiacono, MM; Demartini, G; Dugnani, S; Fraschini, F; Pintucci, JP; Scaglione, F, 1999
)
0.3
" The results of the PA-SME studies, which may be the most clinically relevant pharmacodynamic parameter, confirm the appropriateness of the current once- or twice-daily dosing schedules despite the lack of PAE."( The post-exposure response of Enterobacteriaceae to ceftibuten.
Gould, IM; MacKenzie, FM; Milne, KE, 1999
)
0.3
" The main aim of the study was to establish whether dosing frequency (1 vs 2 or 3 times daily) and other factors influence compliance."( [Patient adherence in respiratory tract infections: ceftibuten versus other antibiotics (PARTICULAR study)].
Kardas, P; Ratajczyk-Pakalska, E, 2001
)
0.31
" Urine samples were taken every 2 h during the whole dosing interval of the particular antibiotic."( Urinary bactericidal activity of oral antibiotics against common urinary tract pathogens in an ex vivo model.
Bedenic, B; Bubonja, M; Budimir, A; Topic, M, 2006
)
0.33
" A ceftibuten murine dosing regimen mimicking ceftibuten 600 mg q12h human exposure was developed and administered alone and in combination with escalating exposures of ledaborbactam."( In vivo pharmacokinetics and pharmacodynamics of ceftibuten/ledaborbactam, a novel oral β-lactam/β-lactamase inhibitor combination.
Asempa, TE; Avery, LM; Fratoni, AJ; Nicolau, DP, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
dicarboxylic acidAny carboxylic acid containing two carboxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency22.38720.003245.467312,589.2998AID2517
aryl hydrocarbon receptorHomo sapiens (human)Potency29.84930.000723.06741,258.9301AID743085
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 15 member 1Homo sapiens (human)Ki565.00000.18003.39339.8000AID238858; AID680839; AID680841; AID681115
Solute carrier family 15 member 2Homo sapiens (human)Ki90.00000.79434.22108.0000AID679554
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki666.66673.00006.47788.5000AID678857; AID681114; AID681347
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 2Homo sapiens (human)
protein transportSolute carrier family 15 member 2Homo sapiens (human)
peptide transportSolute carrier family 15 member 2Homo sapiens (human)
peptidoglycan transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 15 member 2Homo sapiens (human)
dipeptide transportSolute carrier family 15 member 2Homo sapiens (human)
renal absorptionSolute carrier family 15 member 2Homo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwaySolute carrier family 15 member 2Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
antibacterial innate immune responseSolute carrier family 15 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 15 member 2Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
protein bindingSolute carrier family 15 member 2Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 2Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
phagocytic vesicle membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
membraneSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (104)

Assay IDTitleYearJournalArticle
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID679554TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT2-expressing HeLa cells1997Biochimica et biophysica acta, Mar-13, Volume: 1324, Issue:2
Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID679872TP_TRANSPORTER: inhibition of Cephradine uptake (Cephradine: 1000 uM, Ceftibuten: 5000 uM) in PEPT1-expressing LLC-PK1 cells1997The Journal of pharmacology and experimental therapeutics, Jun, Volume: 281, Issue:3
Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics.
AID679866TP_TRANSPORTER: inhibition of Cephradine uptake (Cephradine: 3000 uM, Ceftibuten: 10000 uM) in Xenopus laevis oocytes1995The Journal of pharmacology and experimental therapeutics, Dec, Volume: 275, Issue:3
Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID530834Half life in Neisseria gonorrhoeae infected patient at 400 mg, po2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID531596Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 9 harboring penA gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID681347TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT2-expressing LLC-PK1 cells1997The American journal of physiology, 11, Volume: 273, Issue:5
Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.
AID681350TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT1-expressing LLC-PK1 cells1997The American journal of physiology, 11, Volume: 273, Issue:5
Recognition of beta-lactam antibiotics by rat peptide transporters, PEPT1 and PEPT2, in LLC-PK1 cells.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID530848Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 2 harboring penA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID530855Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 9 harboring penA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1812542In vivo antibacterial activity against Escherichia coli expressing TEM-1/CTX-M-15 infected in C3H/HeJ mouse assessed as log10 reduction in CFU in kidney at 1 to 300 mg/kg, sc administered every 12 hrs for 3 days starting from 4 days post infection and mea
AID679327TP_TRANSPORTER: uptake in PEPT1-expressing LLC-PK1 cells1997The Journal of pharmacology and experimental therapeutics, Jun, Volume: 281, Issue:3
Characterization of stably transfected kidney epithelial cell line expressing rat H+/peptide cotransporter PEPT1: localization of PEPT1 and transport of beta-lactam antibiotics.
AID1812480Antibacterial activity against Escherichia coli expressing CTX-M-15/TEM-1 assessed as concentration required to restore ceftibuten activity incubated for 16 to 20 hrs in presence of 1 ug/ml ceftibuten by broth microdilution method
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID530861Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 4 harboring penA gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID530849Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 3 harboring penA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID531595Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 8 harboring penA gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID678857TP_TRANSPORTER: inhibition of Gly-Sar uptake in SKPT cells1997Biochimica et biophysica acta, Mar-13, Volume: 1324, Issue:2
Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.
AID530835Protein binding in Neisseria gonorrhoeae infected patient serum at 400 mg, po2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID531598Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 2469 isolate 11 harboring penA gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1812481Antibacterial activity against Klebsiella pneumoniae expressing SHV-12/TEM-1 assessed as concentration required to restore ceftibuten activity incubated for 16 to 20 hrs in presence of 1 ug/ml ceftibuten by broth microdilution method
AID1812487Antibacterial activity against Klebsiella pneumoniae expressing OXA-48 assessed as concentration required to restore ceftibuten activity incubated for 16 to 20 hrs in presence of 1 ug/ml ceftibuten by broth microdilution method
AID530860Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 3 harboring penA gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID530854Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 8 harboring penA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID530857Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 2469 isolate 11 harboring penA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID531597Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 10 harboring penA gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID1812484Antibacterial activity against Escherichia coli J53 expressing SHV-5/TEM-1/AmpC assessed as concentration required to restore ceftibuten activity incubated for 16 to 20 hrs in presence of 1 ug/ml ceftibuten by broth microdilution method
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID531594Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 7 harboring penA gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID530851Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 5 harboring penA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID530830Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin resistant penA-negative Neisseria gonorrhoeae by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID238858Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
AID681152TP_TRANSPORTER: uptake in Xenopus laevis oocytes2002Drug metabolism and pharmacokinetics, , Volume: 17, Issue:4
Transporter-mediated Drug Interactions.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID530852Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 6 harboring penA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID530833Cmax in Neisseria gonorrhoeae infected patient at 400 mg, po2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID680841TP_TRANSPORTER: inhibition of Gly-Sar uptake in Caco-2 cells1997Biochimica et biophysica acta, Mar-13, Volume: 1324, Issue:2
Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID681114TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in SKPT cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID530831Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin resistant Neisseria gonorrhoeae by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID1812483Antibacterial activity against Klebsiella pneumoniae 156309 expressing SHV-11/TEM-1/KPC-2 assessed as concentration required to restore ceftibuten activity incubated for 16 to 20 hrs in presence of 1 ug/ml ceftibuten by broth microdilution method
AID530850Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 4 harboring penA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID530858Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 1 harboring penA gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID531060Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 5 harboring penA gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID530832Oral bioavailability in Neisseria gonorrhoeae infected patient at 400 mg, po2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID680839TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT1-expressing HeLa cells1997Biochimica et biophysica acta, Mar-13, Volume: 1324, Issue:2
Interaction of anionic cephalosporins with the intestinal and renal peptide transporters PEPT 1 and PEPT 2.
AID530847Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 1 harboring penA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID1812543In vivo antibacterial activity against Escherichia coli expressing TEM-1/CTX-M-15 infected in C3H/HeJ mouse assessed as log10 reduction in CFU in bladder at 1 to 300 mg/kg, sc administered every 12 hrs for 3 days starting from 4 days post infection and me
AID530853Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 7 harboring penA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID764529Chemical stability of the compound in simulated gastric fluid assessed as compound remaining at 10 uM after 60 mins at pH 1.22013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Synthesis, pH-dependent, and plasma stability of meropenem prodrugs for potential use against drug-resistant tuberculosis.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1812486Antibacterial activity against Escherichia coli 664507 expressing OXA-48 assessed as concentration required to restore ceftibuten activity incubated for 16 to 20 hrs in presence of 1 ug/ml ceftibuten by broth microdilution method
AID530859Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 2 harboring penA gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID681115TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in Caco-2 cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1812482Antibacterial activity against Escherichia coli 786978 expressing KPC assessed as concentration required to restore ceftibuten activity incubated for 16 to 20 hrs in presence of 1 ug/ml ceftibuten by broth microdilution method
AID530856Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 10 harboring penA gene by agar dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID1812485Antibacterial activity against Klebsiella pneumoniae 196477 expressing AmpC/CMY-2/TEM-1/CTX-M-15 assessed as concentration required to restore ceftibuten activity incubated for 16 to 20 hrs in presence of 1 ug/ml ceftibuten by broth microdilution method
AID679951TP_TRANSPORTER: uptake in Xenopus laevis oocytes1995The Journal of pharmacology and experimental therapeutics, Dec, Volume: 275, Issue:3
Cloning and characterization of a rat H+/peptide cotransporter mediating absorption of beta-lactam antibiotics in the intestine and kidney.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID531593Antimicrobial activity against penicillin-,ofloxacin- and tetracyclin-resistant Neisseria gonorrhoeae multiantigen sequence type 835 isolate 6 harboring penA gene by disk diffusion method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
Ceftibuten resistance and treatment failure of Neisseria gonorrhoeae infection.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1812544In vivo antibacterial activity against Escherichia coli expressing TEM-1/CTX-M-15 infected in C3H/HeJ mouse assessed as log10 reduction in CFU in urine at 1 to 300 mg/kg, sc administered every 12 hrs for 3 days starting from 4 days post infection and meas
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (202)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (5.94)18.7374
1990's114 (56.44)18.2507
2000's51 (25.25)29.6817
2010's17 (8.42)24.3611
2020's8 (3.96)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.35 (24.57)
Research Supply Index5.65 (2.92)
Research Growth Index5.37 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials49 (20.85%)5.53%
Reviews18 (7.66%)6.00%
Case Studies5 (2.13%)4.05%
Observational2 (0.85%)0.25%
Other161 (68.51%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]